Martin BR - Search Results

1

In vitro and in vivo effects of cocaine and selected local anesthetics on the dopamine transporter.

Woodward JJ, Compton DM, Balster RL, Martin BR. Woodward JJ, et al. Among authors: martin br. Eur J Pharmacol. 1995 Apr 13;277(1):7-13. doi: 10.1016/0014-2999(95)00042-j. Eur J Pharmacol. 1995. PMID: 7635175

2

In vivo characterization of a novel inhibitor of CNS nicotinic receptors.

Damaj MI, Wiley JL, Martin BR, Papke RL. Damaj MI, et al. Among authors: martin br. Eur J Pharmacol. 2005 Oct 3;521(1-3):43-8. doi: 10.1016/j.ejphar.2005.06.056. Epub 2005 Sep 21. Eur J Pharmacol. 2005. PMID: 16181622

3

Prolonged recovery rate of CB1 receptor adaptation after cessation of long-term cannabinoid administration.

Sim-Selley LJ, Schechter NS, Rorrer WK, Dalton GD, Hernandez J, Martin BR, Selley DE. Sim-Selley LJ, et al. Among authors: martin br. Mol Pharmacol. 2006 Sep;70(3):986-96. doi: 10.1124/mol.105.019612. Epub 2006 Jun 7. Mol Pharmacol. 2006. PMID: 16760363

4

Inhibition of monoacylglycerol lipase and fatty acid amide hydrolase by analogues of 2-arachidonoylglycerol.

Ghafouri N, Tiger G, Razdan RK, Mahadevan A, Pertwee RG, Martin BR, Fowler CJ. Ghafouri N, et al. Among authors: martin br. Br J Pharmacol. 2004 Nov;143(6):774-84. doi: 10.1038/sj.bjp.0705948. Epub 2004 Oct 18. Br J Pharmacol. 2004. PMID: 15492019 Free PMC article.

5

Long-term administration of Delta9-tetrahydrocannabinol desensitizes CB1-, adenosine A1-, and GABAB-mediated inhibition of adenylyl cyclase in mouse cerebellum.

Selley DE, Cassidy MP, Martin BR, Sim-Selley LJ. Selley DE, et al. Among authors: martin br. Mol Pharmacol. 2004 Nov;66(5):1275-84. doi: 10.1124/mol.104.000604. Epub 2004 Jul 30. Mol Pharmacol. 2004. PMID: 15286206

6

Cannabinoid pharmacological properties common to other centrally acting drugs.

Wiley JL, Martin BR. Wiley JL, et al. Among authors: martin br. Eur J Pharmacol. 2003 Jun 27;471(3):185-93. doi: 10.1016/s0014-2999(03)01856-9. Eur J Pharmacol. 2003. PMID: 12826237

7

Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB(1) receptor antagonist.

Wiley JL, Breivogel CS, Mahadevan A, Pertwee RG, Cascio MG, Bolognini D, Huffman JW, Walentiny DM, Vann RE, Razdan RK, Martin BR. Wiley JL, et al. Among authors: martin br. Eur J Pharmacol. 2011 Jan 25;651(1-3):96-105. doi: 10.1016/j.ejphar.2010.10.085. Epub 2010 Nov 27. Eur J Pharmacol. 2011. PMID: 21114999 Free PMC article.

8

Discriminative stimulus properties of delta9-tetrahydrocannabinol (THC) in C57Bl/6J mice.

Vann RE, Warner JA, Bushell K, Huffman JW, Martin BR, Wiley JL. Vann RE, et al. Among authors: martin br. Eur J Pharmacol. 2009 Aug 1;615(1-3):102-7. doi: 10.1016/j.ejphar.2009.05.010. Epub 2009 May 23. Eur J Pharmacol. 2009. PMID: 19470387 Free PMC article.

9

Dose-related differences in the regional pattern of cannabinoid receptor adaptation and in vivo tolerance development to delta9-tetrahydrocannabinol.

McKinney DL, Cassidy MP, Collier LM, Martin BR, Wiley JL, Selley DE, Sim-Selley LJ. McKinney DL, et al. Among authors: martin br. J Pharmacol Exp Ther. 2008 Feb;324(2):664-73. doi: 10.1124/jpet.107.130328. Epub 2007 Oct 29. J Pharmacol Exp Ther. 2008. PMID: 17967938 Free PMC article.

10

Endocannabinoids block status epilepticus in cultured hippocampal neurons.

Deshpande LS, Blair RE, Ziobro JM, Sombati S, Martin BR, DeLorenzo RJ. Deshpande LS, et al. Among authors: martin br. Eur J Pharmacol. 2007 Mar 8;558(1-3):52-9. doi: 10.1016/j.ejphar.2006.11.030. Epub 2006 Nov 22. Eur J Pharmacol. 2007. PMID: 17174949 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results